Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature

Table 1

Summary of cases reporting dasatinib-induced hypopigmentation.

Age (years)	Malignancy	Dasatinib dose (mg)	Time to onset of depigmentation (weeks)	Time to repigmentation (weeks)	Ref
52	Metastatic hemangiopericytoma	70 (twice daily)	8	4–6	[1]
29	Chronic myelogenous leukemia	70 (once daily)	6–8	N/A	[4]
16	Acute lymphoblastic leukemia	100 (twice daily)	4	N/A	[5]
27	Chronic myelogenous leukemia	100 (once daily)	24	N/A	[6]
56	Chronic myelogenous leukemia	70 (once daily)	8	8	[7]